Yunnan Botanee Bio-Technology Group Co Ltd (300957) - Total Liabilities
Based on the latest financial reports, Yunnan Botanee Bio-Technology Group Co Ltd (300957) has total liabilities worth CN¥2.05 Billion CNY (≈ $299.66 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300957 net assets growth trend to track the company's year-over-year net asset growth rate.
Yunnan Botanee Bio-Technology Group Co Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Yunnan Botanee Bio-Technology Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Yunnan Botanee Bio-Technology Group Co L free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Yunnan Botanee Bio-Technology Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yunnan Botanee Bio-Technology Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
China | CN¥1.39 Billion |
|
Computer Age Management Services Limited
NSE:CAMS
|
India | Rs4.90 Billion |
|
5N Plus Inc.
TO:VNP
|
Canada | CA$302.32 Million |
|
FADU Inc.
KQ:440110
|
Korea | ₩47.55 Billion |
|
Olin Corporation
NYSE:OLN
|
USA | $5.40 Billion |
|
Hubei Yihua Chemical Industry Co Ltd
SHE:000422
|
China | CN¥33.15 Billion |
|
Southchip Semiconductor Technology (Shanghai) Co. Ltd. A
SHG:688484
|
China | CN¥751.22 Million |
|
Simplo Technology Co Ltd
TWO:6121
|
Taiwan | NT$37.50 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Yunnan Botanee Bio-Technology Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300957 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yunnan Botanee Bio-Technology Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yunnan Botanee Bio-Technology Group Co Ltd (2017–2025)
The table below shows the annual total liabilities of Yunnan Botanee Bio-Technology Group Co Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.04 Billion ≈ $298.05 Million |
-3.73% |
| 2024-12-31 | CN¥2.12 Billion ≈ $309.60 Million |
+41.89% |
| 2023-12-31 | CN¥1.49 Billion ≈ $218.20 Million |
+33.46% |
| 2022-12-31 | CN¥1.12 Billion ≈ $163.49 Million |
+8.05% |
| 2021-12-31 | CN¥1.03 Billion ≈ $151.31 Million |
+114.74% |
| 2020-12-31 | CN¥481.52 Million ≈ $70.46 Million |
+49.16% |
| 2019-12-31 | CN¥322.82 Million ≈ $47.24 Million |
+3.10% |
| 2018-12-31 | CN¥313.11 Million ≈ $45.82 Million |
+30.79% |
| 2017-12-31 | CN¥239.40 Million ≈ $35.03 Million |
-- |
About Yunnan Botanee Bio-Technology Group Co Ltd
Yunnan Botanee Bio-Technology Group Co.LTD, together with its subsidiaries, engages in the research, development, production, and sale of cosmetics in China and internationally. It operates through Skin Care Products, Medical Instruments, and Makeup segments. The company offers face creams, toners, masks, serums, and lotions; and makeup products, including primers, powders, BB creams, and makeup … Read more